MA40403A - Méthodes de traitement de paramyxovirus - Google Patents
Méthodes de traitement de paramyxovirusInfo
- Publication number
- MA40403A MA40403A MA040403A MA40403A MA40403A MA 40403 A MA40403 A MA 40403A MA 040403 A MA040403 A MA 040403A MA 40403 A MA40403 A MA 40403A MA 40403 A MA40403 A MA 40403A
- Authority
- MA
- Morocco
- Prior art keywords
- treating
- methods
- paramyxoviruses
- methylpropanoate
- cytidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Abstract
La présente invention concerne des procédés pour l'amélioration et/ou le traitement d'une infection à paramyxovirus, ou l'inhibition de la réplication d'un paramyxovirus, par l'utilisation de 3',5'-(2-méthylpropanoate-4'-c-(chlorométhyl)-2'-désoxy-2'-fluoro-cytidine (composé a)), le composé (a) ou son sel pharmaceutiquement acceptable pouvant fournir 4'-c-chlorométhyl-2'-désoxy-2'-fluoro-5'- (tétrahydrogène triphosphate)-cytidine ou son sel pharmaceutiquement acceptable (composé (b)).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462027719P | 2014-07-22 | 2014-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40403A true MA40403A (fr) | 2017-05-31 |
Family
ID=55163588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040403A MA40403A (fr) | 2014-07-22 | 2015-07-20 | Méthodes de traitement de paramyxovirus |
Country Status (13)
Country | Link |
---|---|
US (1) | US20160022724A1 (fr) |
EP (1) | EP3171878A4 (fr) |
JP (1) | JP2017525681A (fr) |
KR (1) | KR20170031231A (fr) |
AU (1) | AU2015294343A1 (fr) |
BR (1) | BR112017001162A2 (fr) |
CA (1) | CA2955604A1 (fr) |
CL (1) | CL2017000156A1 (fr) |
MA (1) | MA40403A (fr) |
MX (1) | MX2017000983A (fr) |
RU (1) | RU2017105470A (fr) |
TW (1) | TW201609104A (fr) |
WO (1) | WO2016014398A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096680A1 (fr) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Analogues de nucléotide phosphorothioate substitués |
ES2702060T3 (es) | 2011-12-22 | 2019-02-27 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y sus análogos |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
KR102168621B1 (ko) | 2012-12-21 | 2020-10-22 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
AU2013361193B2 (en) | 2012-12-21 | 2018-05-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2014165704A1 (fr) | 2013-04-05 | 2014-10-09 | Vertex Pharmaceuticals, Inc. | Traitement contre une infection par le virus de l'hépatite c utilisant une combinaison de composés |
ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
UA118760C2 (uk) | 2013-06-26 | 2019-03-11 | Аліос Біофарма, Інк. | Заміщені нуклеозиди, нуклеотиди та їх аналоги |
WO2015054465A1 (fr) | 2013-10-11 | 2015-04-16 | Alios Biopharma, Inc. | Nucléosides substitués, nucléotides substitués et analogues de ceux-ci |
AP2016009653A0 (en) | 2014-06-24 | 2016-12-31 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
EA201692535A1 (ru) | 2014-06-24 | 2017-05-31 | Элиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
US20160045528A1 (en) * | 2014-08-05 | 2016-02-18 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
US9908914B2 (en) | 2014-10-28 | 2018-03-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
EP3268368A4 (fr) | 2015-03-11 | 2018-11-14 | Alios Biopharma, Inc. | Composés d'aza-pyridone et leurs utilisations |
WO2018081449A1 (fr) * | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Méthode pour le traitement d'une infection par le virus respiratoire syncytial |
WO2018222774A1 (fr) * | 2017-05-30 | 2018-12-06 | Alios Biopharma, Inc. | Méthodes de traitement des pneumovirus |
CN113462656B (zh) * | 2021-03-24 | 2022-09-30 | 兰州生物制品研究所有限责任公司 | 一种人三型副流感病毒冷适应温度敏感株及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA926440B (en) * | 1991-08-26 | 1993-06-07 | Scripps Research Inst | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus. |
JPH0859508A (ja) * | 1994-08-16 | 1996-03-05 | Teijin Ltd | サイトメガロウイルス網膜炎予防または治療剤 |
MX2012015292A (es) * | 2010-06-24 | 2013-05-30 | Gilead Sciences Inc | Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales. |
ES2702060T3 (es) * | 2011-12-22 | 2019-02-27 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y sus análogos |
MX361460B (es) * | 2012-03-21 | 2018-12-06 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos. |
-
2015
- 2015-07-20 WO PCT/US2015/041111 patent/WO2016014398A1/fr active Application Filing
- 2015-07-20 RU RU2017105470A patent/RU2017105470A/ru not_active Application Discontinuation
- 2015-07-20 MA MA040403A patent/MA40403A/fr unknown
- 2015-07-20 US US14/804,034 patent/US20160022724A1/en not_active Abandoned
- 2015-07-20 JP JP2017503609A patent/JP2017525681A/ja active Pending
- 2015-07-20 MX MX2017000983A patent/MX2017000983A/es unknown
- 2015-07-20 BR BR112017001162A patent/BR112017001162A2/pt not_active IP Right Cessation
- 2015-07-20 KR KR1020177004409A patent/KR20170031231A/ko unknown
- 2015-07-20 EP EP15825198.3A patent/EP3171878A4/fr not_active Withdrawn
- 2015-07-20 CA CA2955604A patent/CA2955604A1/fr not_active Abandoned
- 2015-07-20 AU AU2015294343A patent/AU2015294343A1/en not_active Abandoned
- 2015-07-22 TW TW104123747A patent/TW201609104A/zh unknown
-
2017
- 2017-01-20 CL CL2017000156A patent/CL2017000156A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201609104A (zh) | 2016-03-16 |
CA2955604A1 (fr) | 2016-01-28 |
US20160022724A1 (en) | 2016-01-28 |
CL2017000156A1 (es) | 2017-11-03 |
JP2017525681A (ja) | 2017-09-07 |
BR112017001162A2 (pt) | 2017-11-14 |
KR20170031231A (ko) | 2017-03-20 |
WO2016014398A1 (fr) | 2016-01-28 |
RU2017105470A3 (fr) | 2019-02-28 |
MX2017000983A (es) | 2017-09-01 |
RU2017105470A (ru) | 2018-08-22 |
AU2015294343A1 (en) | 2017-02-02 |
EP3171878A1 (fr) | 2017-05-31 |
EP3171878A4 (fr) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40403A (fr) | Méthodes de traitement de paramyxovirus | |
SG10201901010PA (en) | Combination therapy for treating a paramyxovirus | |
IL276883A (en) | "Compositions, devices, systems, kits and methods for treating skin conditions" | |
WO2016044556A3 (fr) | Inhibiteurs d'arginine méthyltransférase et leurs utilisations | |
PH12015501588B1 (en) | Compounds and methods for treating bacterial infections | |
EP3258868A4 (fr) | Dispositifs, systèmes, et procédés de fixation osseuse semi-rigide | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
EP3212658A4 (fr) | Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer | |
PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
MX2017013047A (es) | Tratamiento de dolor. | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
HUE043553T2 (hu) | Spiroindolin vegyületek a légúti óriás sejtes vírusfertõzés (RSV) kezeléséhez és megelõzéséhez | |
MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 | |
EP3574089A4 (fr) | Agent antiviral et méthode de traitement d'une infection virale | |
AU2016234411B2 (en) | Respiratory infection treating agent | |
EP3253312A4 (fr) | Plaques osseuses, systèmes et procédés d'utilisation | |
MX2019005504A (es) | Potenciadores de bmp. | |
MY186775A (en) | Antibacterial compositions and methods | |
MX2018012587A (es) | (+)-azasetron para uso en el tratamiento de trastornos del oido. | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
BR112017004947A2 (pt) | composto ou sal farmaceuticamente aceitável, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento de mieloma múltiplo. |